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Identity 
Other names: CAK; CD167; DDR; EDDR1; HGK2; 
MCK10; NEP; NTRK4; PTK3; PTK3A; RTK6; TRKE 




The DDR1 gene comprises 17 exons and spans 12  
kb of the genomic sequence on chromosome 6 (from 
position 30851861 bp to 30867933 bp in the positive 
strand orientation). 
Transcription 
The 3840-bp mRNA is transcribed in a centromeric to 
telomeric orientation. Alternative splicing can occur, 
and 5 named isoforms (DDR1a-e) are recognised. 
Pseudogene 
No pseudogene has been described. 
 
Genomic organisation of the DDR1 gene on chromosome 6. Exons that are implicated in the alternative splicing process of the DDR1 
gene are represented by open boxes. The alternative splicing process of exon 10 to exon 14 generates 5 DDR1 isoforms, which are 
affixed a-e. 
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Protein 
 
Schematic diagram of the DDR1 protein and localization of 
the DDR1 Tyrosine phosphorylated sites at intracellular 
domain. 
Description 
DDR1 belongs to the DDRs subfamily of tyrosine 
kinase receptors. This subfamily is composed of only 
two members, DDR1 and DDR2, and it is distinguished 
by an extracellular domain that is homologous to the 
carbohydrate-binding lectin discoidin-I in 
Dictyostelium discoideum. The Discoidin domain is 
essential for the ability of DDRs to bind ligands. To-
date, collagen is the only unique DDR1 ligand that has 
been identified. Five isoforms of DDR1 that are 
generated by alternative splicing have been described. 
The longest DDR1 transcript codes for the full-length 
receptor (DDR1c isoform) and is composed of 919 
amino acids. DDR1a and DDR1b isoforms lack 37 
amino acids in the juxtamembrane domain or 6 amino 
acids in the kinase domain. DDR1d and DDR1e 
isoforms are C-terminally truncated receptors. DDR1d 
lacks exons 11 and 12 causing a frame-shift mutation 
that generates a stop codon and premature termination 
of transcription. Finally, DDR1e lacks exons 11 and 12 
as well as the first half of exon 10 (Alves et al., 1995). 
Expression 
DDR1 is ubiquitously expressed in a variety of 
epithelial tissues (Alves et al., 1995; Curat and Vogel, 
2002; Ferri et al., 2004; Hou et al., 2001; Mohan et al., 
2001; Sakamoto et al., 2001; Tanaka et al., 1998). 
DDR1 is also expressed in endothelial blood capillary 
cells and oligodendrocytes in the human brain (Franco-
Pons et al., 2009; Roig et al., 2010). DDR1 is 
significantly overexpressed in several human cancers 
(Barker et al., 1995; Colas et al., 2011; Ford et al., 
2007; Hajdu et al., 2010; Heinzelmann-Schwarz et al., 
2004; Laval et al., 1994; Nemoto et al., 1997; Park et 
al., 2007; Tun et al., 2011; Weiner et al., 1996; Weiner 
et al., 2000; Yamanaka et al., 2006; Yoshida et al., 
2007) and carcinoma cell lines (Alves et al., 1995; Gu 




Receptor tyrosine kinases are key components of 
several signal transduction pathways. These kinases 
control multiple cellular processes, including motility, 
proliferation, differentiation, metabolism and survival. 
DDR1 is actively involved in tumorigenesis and 
promotes the proliferation of neoplasic cells. The 
interaction of DDR1 and Notch1 displays a prosurvival 
effect (Kim et al., 2011). DDR1 participates in the 
collective migration of cancer cells by coordinating the 
cell polarity regulators Par3 and Par6 (Hidalgo-Carcedo 
et al., 2011). 
Homology 
- P. troglodytes, discoidin domain receptor tyrosine 
kinase 1, DDR1 
- C. lupus, discoidin domain receptor tyrosine kinase 1, 
DDR1 
- M. musculus, discoidin domain receptor family 
member 1, Ddr1 
- R. norvegicus, discoidin domain receptor tyrosine 
kinase 1 
- D. rerio, discoidin domain receptor family member 1 
Mutations 
Note 
Few somatic mutations have been described. Four 
mutations (G1486T, A496S, CC2469/2470TT, 
R824W) have been identified in a cohort of 26 primary 
lung neoplasms (Davies et al., 2005). One somatic 
mutation (A803V) was found in 4 acute myeloid 
leukaemia patients (Tomasson et al., 2008). 












DDR1 overexpression was observed in human primary 
breast tumours samples compared to that in normal 
breast tissues (Barker et al., 1995). In addition, invasive 
ductal and lobular carcinomas showed differential 
expression of DDR1. DDR1 was downregulated in 
lobular carcinomas (Turashvili et al., 2007a; Turashvili 
et al., 2007b). 
Osteosarcoma 
Note 
The DDR1 promoter presents a potential p53 binding-
site. A previous study has shown that p53 expression 
upregulated the mRNA expression levels of DDR1 in 
human osteosarcoma cells (Sakuma et al., 1996). 
Oesophageal cancer 
Note 
The overexpression of DDR1 was reported in 12 
carcinomatous oesophageal tissues compared to that in 
normal tissues. Furthermore, a positive correlation was 
identified between DDR1 mRNA expression and the 




DDR1 was highly expressed in 158 histological 
subtypes of primary epithelial ovarian cancers (EOC) 
compared to that in normal ovarian surface epithelium 
samples (Heinzelmann-Schwarz et al., 2004). 
Endometrial cancer 
Note 
DDR1 has been implicated as a potential molecular 
marker of endometrial cancer (Colas et al., 2011; 
Domenyuk et al., 2007). A gene expression screening 
of 52 carcinomas samples showed differential 
expression of several genes, including the DDR1 gene. 
These data were also demonstrated in 50 tumoural and 
non-tumoural uterine aspirates (Colas et al., 2011). 
Brain tumours 
Note 
DDR1 was originally isolated in malignant childhood 
brain tumours, which overexpressed DDR1 (Weiner et 
al., 1996). Replicable findings were found in metastatic 
brain neoplasms and glioma cells (Yamanaka et al., 
2006; Weiner et al., 2000). In glioma cells, DDR1 was 
involved in cell proliferation and invasion via cell 
interactions with the extracellular matrix (Ram et al., 
2005; Yamanaka et al., 2006). Moreover, a study on 
DDR1a and DDR1b isoforms overexpression in glioma 
cells has identified distinct roles for each DDR1 
isoforms in the cell attachment process, which is 
mediated by collagen I (Ram et al., 2005). The analysis 
of the expression profile in mice that had PDGF-
induced glioma showed overexpression of DDR1 
(Johansson et al., 2005). 
Primary central nervous system 
lymphoma (PCNSL) 
Note 
A PCNSL pathway analysis revealed upregulation of 
DDR1 expression in the extracellular matrix and the 
adhesion-related pathways (Tun et al., 2011). 
Pituitary adenoma 
Note 
In different subtypes of pituitary adenoma, DDR1 
expression was related to the hormonal background. 
DDR1 was more highly expressed in macroadenomas, 
compared to microadenomas, and in PRL- and GH-
producing adenomas (Yoshida et al., 2007). 
Lung cancer 
Note 
DDR1 was upregulated in tumour lung tissue compared 
to that in normal tissue and was an independent 
favourable predictor for prognosis (Ford et al., 2007). 
Similarly, DDR1 was highly phosphorylated in non-
small cell lung cancer (NSCLC) (Rikova et al., 2007). 
One study described the presence of DDR1 somatic 
mutations in lung cancer (Davies et al., 2005). 
However, no mutations were detected in another lung 
cancer study (Ford et al., 2007). 
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Liver cancer 
Note 
DDR1a and DDR1b isoforms were overexpressed in 
hepatocellular carcinoma cell lines HLE and Huh-7. 
DDR1 isoform overexpression enhanced the migration 
and invasion of the hepatocellular carcinoma cell lines 
in association with the matrix metalloproteinases 
MMP2 and MMP9 (Park et al., 2007). 
The downregulation of miR-199a-5p, which is a direct 
target of DDR1, deregulated DDR1 functionality and 
increased cell invasion in human hepatocellular 
carcinoma (HCC) (Shen et al., 2010). 
Finally, a profiling study on receptor tyrosine kinase 
phosphorylation in cholangiocarcinoma patients 
showed high levels of phosphorylation of DDR1 and 
other tyrosine kinases in tumour tissues in comparison 
to para-tumour tissues (Gu et al., 2011). 
Mesenchymal neoplasm 
Note 
Solitary fibrous tumour (SFT) expression profiling of 
23 samples showed an over-expression of several 
receptor tyrosine kinase genes, including DDR1. 
However, no mutations were identified using cDNA 
sequencing (Hajdu et al., 2010). 
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